The resulting rise in blood pressure closes the normal feedback loop by inhibiting renin release, decreasing RAAS activation, and reducing aldosterone production.[2e],[6d]
HTN + Aldosterone Dysregulation
Aldosterone plays a pivotal role in blood pressure regulation but can become dysregulated[1a],[2a]
Aldosterone typically controls blood pressure by regulating salt and water levels[1b],[2b],[5a],[6a],[7]
1RAAS Activation
2Increased BP
3Feedback loop
Decreased renal perfusion and salt concentration leads to renin release and RAAS pathway activation. Angiotensin II stimulates aldosterone production in the adrenal glands, mediated by aldosterone synthase.[1c],[2c],[5b],[6b]
Aldosterone binds to mineralocorticoid receptors in the kidneys, increasing reabsorption of urinary sodium and raising intravascular volume.[1d],[2d],[5c],[6c]
Aldosterone binds to mineralocorticoid receptors in the kidneys, increasing reabsorption of urinary sodium and raising intravascular volume.[1d],[2d],[5c],[6c]
The resulting rise in blood pressure closes the normal feedback loop by inhibiting renin release, decreasing RAAS activation, and reducing aldosterone production.[2e],[6d]
Not all hypertension is the same. Aldosterone may be to blame.[3b],[4c]
Want the latest information about aldosterone dysregulation
and its link to hypertension?
Subscribe NowACE=angiotensin-converting enzyme; BP=blood pressure; HTN=hypertension; RAAS=renin-angiotensin-aldosterone system.
References:
1.
1a 1b 1c 1d Crompton M et al. Biomolecules. 2023;13(6):1004.
2.
2a 2b 2c 2d 2e 2f Papadopoulou-Marketou N et al. Hyperaldosteronism. Endotext [internet]. Updated 6 August 2020. Accessed 11 November 2025. https://www.ncbi.nlm.nih.gov/books/NBK279065/
3.
3a 3b Jones DW et al. J Am Coll Cardiol. 2025;86(18):1567–1678.
4.
4a 4b 4c Brown JM et al. Ann Intern Med. 2020;173(1):10–20.
5.
5a 5b 5c Scott JH et al. Physiology, aldosterone. StatPearls [internet]. Updated 1 May 2023. Accessed 11 November 2025. https://www.ncbi.nlm.nih.gov/books/NBK470339/
6.
6a 6b 6c 6d Triebel H et al. Pflugers Arch—Eur J Physiol. 2024;476(5):705–713.
7.
^ Otsuka H et al. Int J Mol Sci. 2023;24(6):5370.
The information on this website is provided by AstraZeneca for educational purposes only and is intended for Healthcare Professionals only. It should not be used for diagnosing or treating a health problem or disease.
REPORTING OF ADVERSE EVENTS
Reporting adverse events after authorization of a medical product is important. It allows for continued monitoring of the benefit/risk balance of the medicinal product.
Adverse events should be reported to AstraZeneca at https://contactazmedical.astrazeneca.com within 1 business day of Awareness date
TH-28038 I Date of Expiration: April 2028
This website is intended for Healthcare Professionals in Thailand.
TH-28626
© AstraZeneca 2026
Our policies
Information
Contact Us
AstraZeneca (Thailand) Ltd.
Asia Centre Building, 19th Floor,
173/20 South Sathorn Road, Thungmahamek,
Sathorn, Bangkok, 10120, Thailand.
Tel: +66 (2) 739 7400, Fax: +66 (2) 739 7497